Literature DB >> 20631496

Sorafenib and thyrotoxicosis.

D Barbaro.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20631496     DOI： 10.1007/BF03346617

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  5 in total

1.  Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib.

Authors:  I Tamaskar; R Bukowski; P Elson; A G Ioachimescu; L Wood; R Dreicer; T Mekhail; J Garcia; B I Rini
Journal:  Ann Oncol       Date:  2007-10-24       Impact factor: 32.976

Review 2.  Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.

Authors:  Jörg Thomas Hartmann; Michael Haap; Hans-Georg Kopp; Hans-Peter Lipp
Journal:  Curr Drug Metab       Date:  2009-06       Impact factor: 3.731

3.  Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation.

Authors:  Hideaki Miyake; Toshifumi Kurahashi; Kazuki Yamanaka; Yutaka Kondo; Mototsugu Muramaki; Atsushi Takenaka; Taka-Aki Inoue; Masato Fujisawa
Journal:  Urol Oncol       Date:  2009-11-13       Impact factor: 3.498

4.  Thyrotoxicosis during sunitinib treatment for renal cell carcinoma.

Authors:  Mathis Grossmann; Erosha Premaratne; Jayesh Desai; Ian D Davis
Journal:  Clin Endocrinol (Oxf)       Date:  2008-04-03       Impact factor: 3.478

Review 5.  Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.

Authors:  Francesco Torino; Salvatore Maria Corsello; Raffaele Longo; Agnese Barnabei; Giampietro Gasparini
Journal:  Nat Rev Clin Oncol       Date:  2009-04       Impact factor: 66.675
  5 in total
  1 in total

Review 1.  Thyroid dysfunction from antineoplastic agents.

Authors:  Ole-Petter Riksfjord Hamnvik; P Reed Larsen; Ellen Marqusee
Journal:  J Natl Cancer Inst       Date:  2011-10-18       Impact factor: 13.506
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.